240 related articles for article (PubMed ID: 23161835)
1. Potent inhibitors of malarial aspartic proteases, the plasmepsins, by hydroformylation of substituted 7-azanorbornenes.
Aureggi V; Ehmke V; Wieland J; Schweizer WB; Bernet B; Bur D; Meyer S; Rottmann M; Freymond C; Brun R; Breit B; Diederich F
Chemistry; 2013 Jan; 19(1):155-64. PubMed ID: 23161835
[TBL] [Abstract][Full Text] [Related]
2. New organofluorine building blocks: inhibition of the malarial aspartic proteases plasmepsin II and IV by alicyclic alpha,alpha-difluoroketone hydrates.
Fäh C; Hardegger LA; Baitsch L; Schweizer WB; Meyer S; Bur D; Diederich F
Org Biomol Chem; 2009 Oct; 7(19):3947-57. PubMed ID: 19763297
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological evaluation, and modeling studies of inhibitors aimed at the malarial proteases plasmepsins I and II.
Muthas D; Nöteberg D; Sabnis YA; Hamelink E; Vrang L; Samuelsson B; Karlén A; Hallberg A
Bioorg Med Chem; 2005 Sep; 13(18):5371-90. PubMed ID: 16054370
[TBL] [Abstract][Full Text] [Related]
4. Exploiting Structural Dynamics To Design Open-Flap Inhibitors of Malarial Aspartic Proteases.
Bobrovs R; Jaudzems K; Jirgensons A
J Med Chem; 2019 Oct; 62(20):8931-8950. PubMed ID: 31062983
[TBL] [Abstract][Full Text] [Related]
5. Design of new plasmepsin inhibitors: a virtual high throughput screening approach on the EGEE grid.
Kasam V; Zimmermann M; Maass A; Schwichtenberg H; Wolf A; Jacq N; Breton V; Hofmann-Apitius M
J Chem Inf Model; 2007; 47(5):1818-28. PubMed ID: 17727268
[TBL] [Abstract][Full Text] [Related]
6. Azole-based non-peptidomimetic plasmepsin inhibitors.
Kinena L; Leitis G; Kanepe-Lapsa I; Bobrovs R; Jaudzems K; Ozola V; Suna E; Jirgensons A
Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800151. PubMed ID: 30063266
[TBL] [Abstract][Full Text] [Related]
7. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
Hidaka K; Kimura T; Tsuchiya Y; Kamiya M; Ruben AJ; Freire E; Hayashi Y; Kiso Y
Bioorg Med Chem Lett; 2007 Jun; 17(11):3048-52. PubMed ID: 17400453
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of plasmepsin I and plasmepsin II inhibitors with activity in Plasmodium falciparum-infected cultured human erythrocytes.
Nöteberg D; Hamelink E; Hultén J; Wahlgren M; Vrang L; Samuelsson B; Hallberg A
J Med Chem; 2003 Feb; 46(5):734-46. PubMed ID: 12593654
[TBL] [Abstract][Full Text] [Related]
9. Optimization of plasmepsin inhibitor by focusing on similar structural feature with chloroquine to avoid drug-resistant mechanism of Plasmodium falciparum.
Miura T; Hidaka K; Azai Y; Kashimoto K; Kawasaki Y; Chen SE; de Freitas RF; Freire E; Kiso Y
Bioorg Med Chem Lett; 2014 Apr; 24(7):1698-701. PubMed ID: 24631188
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of 2-aminomethyl-4-phenyl-1-azabicyclo[2.2.1]heptanes via LiAlH₄-induced reductive cyclization of 2-(4-chloro-2-cyano-2-phenylbutyl)aziridines and evaluation of their antimalarial activity.
D'hooghe M; Vervisch K; Törnroos KW; Verhaeghe T; Desmet T; Lategan C; Smith PJ; Chibale K; De Kimpe N
Bioorg Med Chem Lett; 2013 Mar; 23(5):1507-10. PubMed ID: 23347684
[TBL] [Abstract][Full Text] [Related]
11. Characterisation of hydrazides and hydrazine derivatives as novel aspartic protease inhibitors.
Ahmed W; Rani M; Khan IA; Iqbal A; Khan KM; Haleem MA; Azim MK
J Enzyme Inhib Med Chem; 2010 Oct; 25(5):673-8. PubMed ID: 20063996
[TBL] [Abstract][Full Text] [Related]
12. Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
Azim MK; Ahmed W; Khan IA; Rao NA; Khan KM
Bioorg Med Chem Lett; 2008 May; 18(9):3011-5. PubMed ID: 18417344
[TBL] [Abstract][Full Text] [Related]
13. Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design.
McKay PB; Peters MB; Carta G; Flood CT; Dempsey E; Bell A; Berry C; Lloyd DG; Fayne D
Bioorg Med Chem Lett; 2011 Jun; 21(11):3335-41. PubMed ID: 21531557
[TBL] [Abstract][Full Text] [Related]
14. Computational inhibitor design against malaria plasmepsins.
Bjelic S; Nervall M; Gutiérrez-de-Terán H; Ersmark K; Hallberg A; Aqvist J
Cell Mol Life Sci; 2007 Sep; 64(17):2285-305. PubMed ID: 17585371
[TBL] [Abstract][Full Text] [Related]
15. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I
PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224
[TBL] [Abstract][Full Text] [Related]
16. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
[No Abstract] [Full Text] [Related]
17. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
[TBL] [Abstract][Full Text] [Related]
18. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target.
Nezami A; Luque I; Kimura T; Kiso Y; Freire E
Biochemistry; 2002 Feb; 41(7):2273-80. PubMed ID: 11841219
[TBL] [Abstract][Full Text] [Related]
19. Predicting functional residues in Plasmodium falciparum plasmepsins by combining sequence and structural analysis with molecular dynamics simulations.
Valiente PA; Batista PR; Pupo A; Pons T; Valencia A; Pascutti PG
Proteins; 2008 Nov; 73(2):440-57. PubMed ID: 18442137
[TBL] [Abstract][Full Text] [Related]
20. Peptidomimetic plasmepsin inhibitors with potent anti-malarial activity and selectivity against cathepsin D.
Zogota R; Kinena L; Withers-Martinez C; Blackman MJ; Bobrovs R; Pantelejevs T; Kanepe-Lapsa I; Ozola V; Jaudzems K; Suna E; Jirgensons A
Eur J Med Chem; 2019 Feb; 163():344-352. PubMed ID: 30529637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]